These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
56 related articles for article (PubMed ID: 8681491)
1. Pharmacokinetics of F105, a human monoclonal antibody, in persons infected with human immunodeficiency virus type 1. Wolfe EJ; Cavacini LA; Samore MH; Posner MR; Kozial C; Spino C; Trapnell CB; Ketter N; Hammer S; Gambertoglio JG Clin Pharmacol Ther; 1996 Jun; 59(6):662-7. PubMed ID: 8681491 [TBL] [Abstract][Full Text] [Related]
2. Phase I study of a human monoclonal antibody directed against the CD4-binding site of HIV type 1 glycoprotein 120. Cavacini LA; Samore MH; Gambertoglio J; Jackson B; Duval M; Wisnewski A; Hammer S; Koziel C; Trapnell C; Posner MR AIDS Res Hum Retroviruses; 1998 May; 14(7):545-50. PubMed ID: 9591708 [TBL] [Abstract][Full Text] [Related]
3. Binding kinetics, uptake and intracellular accumulation of F105, an anti-gp120 human IgG1kappa monoclonal antibody, in HIV-1 infected cells. Clayton R; Ohagen A; Goethals O; Smets A; Van Loock M; Michiels L; Kennedy-Johnston E; Cunningham M; Jiang H; Bola S; Gutshall L; Gunn G; Del Vecchio A; Sarisky R; Hallenberger S; Hertogs K J Virol Methods; 2007 Jan; 139(1):17-23. PubMed ID: 17034868 [TBL] [Abstract][Full Text] [Related]
4. Plasma pharmacokinetics and biological activity of a human immunodeficiency virus type 1 neutralizing human monoclonal antibody, F105, in cynomolgus monkeys. Cavacini LA; Power J; Emes CL; Mace K; Treacy G; Posner MR J Immunother Emphasis Tumor Immunol; 1994 May; 15(4):251-6. PubMed ID: 8061897 [TBL] [Abstract][Full Text] [Related]
5. Toxicity, biological activity, and pharmacokinetics of TXU (anti-CD7)-pokeweed antiviral protein in chimpanzees and adult patients infected with human immunodeficiency virus. Uckun FM; Bellomy K; O'Neill K; Messinger Y; Johnson T; Chen CL J Pharmacol Exp Ther; 1999 Dec; 291(3):1301-7. PubMed ID: 10565855 [TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics and safety of golimumab, a fully human anti-TNF-alpha monoclonal antibody, in subjects with rheumatoid arthritis. Zhou H; Jang H; Fleischmann RM; Bouman-Thio E; Xu Z; Marini JC; Pendley C; Jiao Q; Shankar G; Marciniak SJ; Cohen SB; Rahman MU; Baker D; Mascelli MA; Davis HM; Everitt DE J Clin Pharmacol; 2007 Mar; 47(3):383-96. PubMed ID: 17322150 [TBL] [Abstract][Full Text] [Related]
7. Passive immunization with the anti-HIV-1 human monoclonal antibody (hMAb) 4E10 and the hMAb combination 4E10/2F5/2G12. Armbruster C; Stiegler GM; Vcelar BA; Jäger W; Köller U; Jilch R; Ammann CG; Pruenster M; Stoiber H; Katinger HW J Antimicrob Chemother; 2004 Nov; 54(5):915-20. PubMed ID: 15456731 [TBL] [Abstract][Full Text] [Related]
8. An enzyme-linked immunosorbent assay for therapeutic drug monitoring of infliximab. Ternant D; Mulleman D; Degenne D; Willot S; Guillaumin JM; Watier H; Goupille P; Paintaud G Ther Drug Monit; 2006 Apr; 28(2):169-74. PubMed ID: 16628126 [TBL] [Abstract][Full Text] [Related]
9. Phase I pharmacokinetic and biologic correlative study of mapatumumab, a fully human monoclonal antibody with agonist activity to tumor necrosis factor-related apoptosis-inducing ligand receptor-1. Tolcher AW; Mita M; Meropol NJ; von Mehren M; Patnaik A; Padavic K; Hill M; Mays T; McCoy T; Fox NL; Halpern W; Corey A; Cohen RB J Clin Oncol; 2007 Apr; 25(11):1390-5. PubMed ID: 17416859 [TBL] [Abstract][Full Text] [Related]
10. Safety, pharmacokinetics, and antiviral activity of HGS004, a novel fully human IgG4 monoclonal antibody against CCR5, in HIV-1-infected patients. Lalezari J; Yadavalli GK; Para M; Richmond G; Dejesus E; Brown SJ; Cai W; Chen C; Zhong J; Novello LA; Lederman MM; Subramanian GM J Infect Dis; 2008 Mar; 197(5):721-7. PubMed ID: 18266604 [TBL] [Abstract][Full Text] [Related]
11. Interaction between virion-bound host intercellular adhesion molecule-1 and the high-affinity state of lymphocyte function-associated antigen-1 on target cells renders R5 and X4 isolates of human immunodeficiency virus type 1 more refractory to neutralization. Fortin JF; Cantin R; Bergeron MG; Tremblay MJ Virology; 2000 Mar; 268(2):493-503. PubMed ID: 10704357 [TBL] [Abstract][Full Text] [Related]
12. Curdlan sulfate (CRDS) in a 21-day intravenous tolerance study in human immunodeficiency virus (HIV) and cytomegalovirus (CMV) infected patients: indication of anti-CMV activity with low toxicity. Gordon M; Deeks S; De Marzo C; Goodgame J; Guralnik M; Lang W; Mimura T; Pearce D; Kaneko Y J Med; 1997; 28(1-2):108-28. PubMed ID: 9249617 [TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics and pharmacodynamics of subcutaneous interleukin-2 in HIV-infected patients. Piscitelli SC; Wells MJ; Metcalf JA; Baseler M; Stevens R; Davey RT Pharmacotherapy; 1996; 16(5):754-9. PubMed ID: 8888071 [TBL] [Abstract][Full Text] [Related]
14. Binding of antibodies to virion-associated gp120 molecules of primary-like human immunodeficiency virus type 1 (HIV-1) isolates: effect on HIV-1 infection of macrophages and peripheral blood mononuclear cells. Stamatatos L; Zolla-Pazner S; Gorny MK; Cheng-Mayer C Virology; 1997 Mar; 229(2):360-9. PubMed ID: 9126249 [TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetics of a new human monoclonal antibody against cytomegalovirus. Third communication: correspondence of the idiotype activity and virus neutralization activity of the new monoclonal antibody, regavirumab in rat serum and its pharmacokinetics in rats and monkeys. Arizono H; Sugano T; Kaida S; Shibusawa K; Karasawa Y; Esumi Y; Kondo S; Kiyoki M Arzneimittelforschung; 1994 Jul; 44(7):909-13. PubMed ID: 7945531 [TBL] [Abstract][Full Text] [Related]
16. Monoclonal antibody hNM01 in HIV-infected patients: a phase I study. Dezube BJ; Doweiko JP; Proper JA; Conway B; Hwang L; Terada M; Leece BA; Ohno T; Mastico RA J Clin Virol; 2004 Dec; 31 Suppl 1():S45-7. PubMed ID: 15567093 [TBL] [Abstract][Full Text] [Related]
17. Single-dose safety, pharmacology, and antiviral activity of the human immunodeficiency virus (HIV) type 1 entry inhibitor PRO 542 in HIV-infected adults. Jacobson JM; Lowy I; Fletcher CV; O'Neill TJ; Tran DN; Ketas TJ; Trkola A; Klotman ME; Maddon PJ; Olson WC; Israel RJ J Infect Dis; 2000 Jul; 182(1):326-9. PubMed ID: 10882617 [TBL] [Abstract][Full Text] [Related]
18. Epratuzumab, a humanized anti-CD22 antibody, in aggressive non-Hodgkin's lymphoma: phase I/II clinical trial results. Leonard JP; Coleman M; Ketas JC; Chadburn A; Furman R; Schuster MW; Feldman EJ; Ashe M; Schuster SJ; Wegener WA; Hansen HJ; Ziccardi H; Eschenberg M; Gayko U; Fields SZ; Cesano A; Goldenberg DM Clin Cancer Res; 2004 Aug; 10(16):5327-34. PubMed ID: 15328168 [TBL] [Abstract][Full Text] [Related]
19. Phase I study of etoposide phosphate (etopophos) as a 30-minute infusion on days 1, 3, and 5. Fields SZ; Igwemezie LN; Kaul S; Schacter LP; Schilder RJ; Litam PP; Himpler BS; McAleer C; Wright J; Barbhaiya RH Clin Cancer Res; 1995 Jan; 1(1):105-11. PubMed ID: 9815892 [TBL] [Abstract][Full Text] [Related]
20. A phase I trial of humanized monoclonal antibody A33 in patients with colorectal carcinoma: biodistribution, pharmacokinetics, and quantitative tumor uptake. Scott AM; Lee FT; Jones R; Hopkins W; MacGregor D; Cebon JS; Hannah A; Chong G; U P; Papenfuss A; Rigopoulos A; Sturrock S; Murphy R; Wirth V; Murone C; Smyth FE; Knight S; Welt S; Ritter G; Richards E; Nice EC; Burgess AW; Old LJ Clin Cancer Res; 2005 Jul; 11(13):4810-7. PubMed ID: 16000578 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]